Kezar Life Sciences stock (US49374L1008): Aurinia completes $51.4M acquisition

Aurinia Pharma U.S., Inc. completed its acquisition of Kezar Life Sciences on May 11, 2026, marking the end of the clinical-stage biopharmaceutical company's independent operations. The transaction, which was announced on March 30, 2026, valued Kezar at $51.4 million, with shareholders receiving $6.955 per share in cash plus one non-tradable contingent value right (CVR) per share, according to MarketScreener as of May 12, 2026.

As of: May 12, 2026

By the editorial team – specialized in equity coverage.

Kezar Life Sciences: clinical-stage immunology focus

Kezar Life Sciences was a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The company operated in a highly competitive segment of the biotech industry where clinical-stage assets and pipeline potential drive valuation. Prior to the acquisition, Kezar was backed by Tang Capital Partners, LP, which managed the company's ownership structure and strategic direction.

Transaction structure and shareholder consideration

Under the merger agreement, Kezar shareholders who tendered their shares received $6.955 per share in cash plus one CVR per share. The CVR represents a contingent payment mechanism tied to future milestones or events, though specific CVR terms were not disclosed in available filings. Form 4 filings show that company insiders, including Chief Financial Officer Marc Belsky and director Michael Kauffman, participated in the tender offer, disposing of their equity positions at the merger consideration, according to StockTitan SEC filings as of May 12, 2026.

At the effective time of the merger on May 11, 2026, Kezar became a wholly owned subsidiary of Aurinia Pharma U.S., Inc. All employee stock options were either cancelled for no consideration if out-of-the-money or cash-settled plus CVRs if in-the-money, according to merger terms disclosed in insider trading filings.

Strategic rationale and pipeline integration

Aurinia's acquisition of Kezar represents a consolidation move within the clinical-stage biotech sector. Aurinia, itself a biopharmaceutical company, gains access to Kezar's small molecule pipeline focused on immune-mediated diseases. For US investors, this transaction reflects ongoing M&A activity in the biotech space, where larger or better-capitalized firms acquire clinical-stage assets to expand their therapeutic portfolios and reduce development risk through diversification.

Conclusion

The completion of Aurinia's acquisition of Kezar Life Sciences on May 11, 2026, marks the end of Kezar's public trading history and independent operations. Shareholders received $6.955 per share in cash plus contingent value rights, while the company's clinical-stage pipeline in immune-mediated diseases becomes part of Aurinia's broader therapeutic portfolio. For US investors who held Kezar stock, the transaction provides liquidity at the agreed consideration; for those tracking biotech M&A trends, the deal illustrates continued consolidation in the clinical-stage sector as larger players seek to acquire promising pipelines and reduce development risk.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.